TARDBP and proteostasis deficiencies: Our data showing that dopamine levels are decreased in the context of mutant TDP-43 overexpression led us to hypothesize that pramipexole, a dopamine agonist that has been shown to reverse motor deficits caused by dopamine depletion in Parkinson’s disease patients, may also be protective in the context of TDP-43 proteinopathy.